Wednesday, January 24, 2024
Vivtex Corporation, a biotech company focused on advancing oral biologic therapies for major diseases, has recently initiated a research collaboration with Astellas Pharma Inc., a global pharmaceutical company. The collaboration aims to assess Vivtex's proprietary GI-ORIS™ ("Gut on a chip" and AI) screening and formulation platform technology to aid in the development of new oral versions of a therapeutic candidate provided by Astellas.
Maureen Deehan, CEO of Vivtex, expressed excitement about the collaboration, stating, "We are pleased to embark on this collaboration with Astellas Pharma. In recent years, Vivtex has successfully worked with leading pharma and biotech companies to apply our GI-ORIS™ platform to enhance drug oral bioavailability, potentially creating valuable new product opportunities for patients."
A 2020 study published in Nature Biomedical Engineering by Vivtex scientists demonstrated the potential of the GI-ORIS™ platform in expediting the development of new orally available biologic drugs. The study illustrated the platform's ability to accurately model the absorption of drug molecules in the small intestine, allowing Vivtex to develop novel oral formulations and delivery methods that were previously challenging with existing technologies. Vivtex holds a worldwide, exclusive license from MIT for this foundational technology and its applications in the development of novel oral biologic therapies.
Source: globenewswire.com
